We looked at and reviewed the charts of Halozyme Therapeutics (HALO) on December 23 and wrote: "Continue to hold long positions but raise stop protection to $38 from $35. $48 and then $55 are our price targets."
More from Investing
What's next after this seesaw week? One thing is for sure: More volatility.
I wouldn't want to own NKLA, but I could see riding it for a few days.
Here's why you should stay nimble as you approach MRVL after its post-earnings upswing.
The financial services giant just held its first investor day in three years -- let's open the vault and see what's inside.